Skip to main content

Leukemia

MURANO: Venetoclax–Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
By Phoebe Starr
Leukemia
April 2019, Vol 9, No 4
A2-year duration of combination immunotherapy with ven­etoclax (Venclexta) and rituximab (Ri­tuxan) improved survival compared with standard-of-care chemoimmunotherapy combination with bendamustine (Ben­deka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to follow-up data from the MURANO clinical trial presented at ASH 2018. Early results were first presented at ASH 2017. Read More ›
Management of Acute Myeloid Leukemia with FLT3 Mutation
By Meg Barbor, MPH
Leukemia
July 2018, Vol 8, No 7
In April 2017, the FDA approved midostaurin (Rydapt) as the first tyrosine kinase inhibitor (TKI) for acute myeloid leukemia (AML) with a specific biomarker, FLT3 mutation, marking the introduction of targeted therapy for this notoriously difficult-to-treat type of leukemia. Read More ›
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
Leukemia
Web Exclusives
New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation. Read More ›
Mylotarg Now Approved for the Treatment of Patients with CD33-Positive AML
FDA Approvals, News & Updates, Leukemia
Web Exclusives
On September 1, 2017, the FDA approved gemtuzumab ozogamicin (Mylotarg; Pfi­zer) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), as well as patients aged ≥2 years with relapsed or refractory CD33-positive AML. Read More ›

Page 3 of 4